| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,041 | 0,073 | 19.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.11. | hVIVO PLC - Board appointment & Completion of Board evolution | 1 | RNS | ||
| 12.10. | hVIVO PLC - Appointment of Chief Financial Officer | - | RNS | ||
| 22.09. | hVIVO PLC - Board Changes | - | RNS | ||
| 17.09. | hVIVO H1 2026 slides: record orderbook offsets timing-driven loss | 4 | Investing.com | ||
| 17.09. | hVIVO meldet Verlust für H1 2026 nach Umsatzverschiebung in die zweite Jahreshälfte | 1 | Investing.com Deutsch | ||
| 15.09. | EARNINGS: hVIVO CFO to retire; Personal Group sales and profit climb | 1 | Alliance News | ||
| 15.09. | hVIVO reports H1 revenue decline, orderbook more than doubles | 2 | Investing.com | ||
| HVIVO Aktie jetzt für 0€ handeln | |||||
| 15.09. | hVIVO PLC - Interim Results | - | RNS | ||
| 15.09. | hVIVO PLC - Chief Financial Officer Succession | 1 | RNS | ||
| 08.09. | hVIVO PLC - Holding(s) in Company | - | RNS | ||
| 04.09. | hVIVO PLC - Notice of Results | - | RNS | ||
| 27.08. | hVIVO buys CRS Berlin as expands into dermatology and women's health | 24 | Alliance News | ||
| 27.08. | hVIVO übernimmt CRS Berlin: Expansion in Dermatologie und Frauengesundheit | 4 | Investing.com Deutsch | ||
| 27.08. | hVIVO acquires CRS Berlin for dermatology, women's health trials | 4 | Investing.com | ||
| 27.08. | hVIVO plc: hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets | 981 | GlobeNewswire (Europe) | London, UK - 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition... ► Artikel lesen | |
| 27.08. | hVIVO PLC - hVIVO acquires CRS Berlin | 3 | RNS | ||
| 23.07. | hVIVO PLC - H1 2026 Trading Update | - | RNS | ||
| 13.07. | hVIVO PLC - Change of Auditor | - | RNS | ||
| 09.06. | hVIVO PLC - Holding(s) in Company | 1 | RNS | ||
| 01.06. | hVIVO schließt Beratungsvertrag mit Decoy Therapeutics | 2 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CERENOME | 0,585 | +23,55 % | Cerenome outlines $10M-$12.5M 2026 gross billings run rate exit while targeting mid-2027 REYOBIQ top line data | ||
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | NuGen Medical Devices Inc.: NuGen Medical Devices Provides Update on Health Canada Licence Application | Toronto, Ontario--(Newsfile Corp. - November 13, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a developer of needle-free drug delivery technology, provides an update regarding... ► Artikel lesen | |
| UNIDOC HEALTH | 0,028 | -7,28 % | CSE Bulletin: Reinstatement - UniDoc Health Corp. (UDOC) | Le 7 octobre/October 2026
Effective immediately, UniDoc Health Corp. will be reinstated for trading.
The Company has rectified the default situation that gave rise to the suspension.
__________________________
En... ► Artikel lesen | |
| NETRAMARK | 0,296 | -17,09 % | NetraMark Holdings Inc.: NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness | TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 3,584 | -9,19 % | Nomura Cuts JD HEALTH TP to HKD51; 4Q Revenue Outlook Weakens but Margin Expansion May Persist | ||
| LIFEWARD | 2,930 | -8,44 % | Lifeward GAAP EPS of -$1.32 misses by $0.50, revenue of $5.43M misses by $1.81M | ||
| IMUNON | 0,400 | -9,09 % | Imunon targets 50% OVATION-3 enrollment in Q1 2028 while aiming for interim analysis in Q1 2030 | ||
| ROCKWELL MEDICAL | 6,260 | +2,62 % | Rockwell Medical expects $400M-$450M combined annual revenue as it targets mid-2027 Vantive closing | ||
| VIRIDIAN THERAPEUTICS | 28,200 | +2,17 % | BofA stuft Viridian Therapeutics mit "Buy" ein - Großes Potenzial bei TED-Medikament | ||
| SINTX TECHNOLOGIES | 1,190 | -2,06 % | SINTX secures patents in Europe, Canada, Japan and South Korea | ||
| AETHLON MEDICAL | 4,825 | -4,64 % | Aethlon Medical GAAP EPS of -$2.60 beats by $0.10 | ||
| SAVARIA | 20,000 | +0,50 % | Savaria Corp: Savaria receives TSX approval for buyback | ||
| NEURONETICS | 1,180 | +2,61 % | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCH THERAPEUTICS | - | - | BC Securities Commission: BCSC bans Dhillon for Arch Therapeutics scheme |